nevirapine has been researched along with Genetic Predisposition in 16 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nevirapine is used in developing countries for the treatment of HIV infection, but its use is associated with rare serious adverse reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)." | 7.88 | A multivariate genetic analysis confirms rs5010528 in the human leucocyte antigen-C locus as a significant contributor to Stevens-Johnson syndrome/toxic epidermal necrolysis susceptibility in a Mozambique HIV population treated with nevirapine. ( Borgiani, P; Ciccacci, C; Ciccacci, F; Lucaroni, F; Mancinelli, S; Marazzi, MC; Novelli, G; Palombi, L; Politi, C, 2018) |
| "Nevirapine has been used as antiretroviral agent since early '90." | 5.48 | Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. ( Cattaneo, D; Cheli, S; Clementi, E; Di Cristo, V; Falvella, FS; Galli, M; Giacomelli, A; Lupo, A; Oreni, ML; Renisi, G; Ridolfo, AL; Riva, A; Rusconi, S, 2018) |
| "Nevirapine is used in developing countries for the treatment of HIV infection, but its use is associated with rare serious adverse reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)." | 3.88 | A multivariate genetic analysis confirms rs5010528 in the human leucocyte antigen-C locus as a significant contributor to Stevens-Johnson syndrome/toxic epidermal necrolysis susceptibility in a Mozambique HIV population treated with nevirapine. ( Borgiani, P; Ciccacci, C; Ciccacci, F; Lucaroni, F; Mancinelli, S; Marazzi, MC; Novelli, G; Palombi, L; Politi, C, 2018) |
| "Nevirapine has been used as antiretroviral agent since early '90." | 1.48 | Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. ( Cattaneo, D; Cheli, S; Clementi, E; Di Cristo, V; Falvella, FS; Galli, M; Giacomelli, A; Lupo, A; Oreni, ML; Renisi, G; Ridolfo, AL; Riva, A; Rusconi, S, 2018) |
| "Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are severe adverse drug reactions, characterized by extensive epidermal detachment and erosions of mucous membrane." | 1.42 | A pharmacogenetics study in Mozambican patients treated with nevirapine: full resequencing of TRAF3IP2 gene shows a novel association with SJS/TEN susceptibility. ( Borgiani, P; Buonomo, E; Ciccacci, C; Giardina, E; Mancinelli, S; Marazzi, MC; Novelli, G; Palombi, L; Rufini, S; Scarcella, P, 2015) |
| "Nevirapine (NVP) is an anti-retroviral drug used for the treatment of HIV infection, that may cause several severe adverse events, including Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis (SJS/TEN)." | 1.40 | HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis susceptibility in a population from Mozambique. ( Borgiani, P; Ciccacci, C; Di Fusco, D; Erba, F; Mancinelli, S; Marazzi, MC; Novelli, G; Palombi, L, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Celerino da Silva, R | 1 |
| Segat, L | 1 |
| Kuhn, L | 3 |
| Chies, JAB | 1 |
| Crovella, S | 1 |
| Ciccacci, C | 4 |
| Latini, A | 1 |
| Politi, C | 2 |
| Mancinelli, S | 4 |
| Marazzi, MC | 4 |
| Novelli, G | 4 |
| Palombi, L | 4 |
| Borgiani, P | 4 |
| Ciccacci, F | 1 |
| Lucaroni, F | 1 |
| Ahir-Bist, S | 1 |
| Chavan, V | 1 |
| Samant-Mavani, P | 1 |
| Nanavati, R | 1 |
| Mehta, P | 1 |
| Mania-Pramanik, J | 1 |
| Giacomelli, A | 1 |
| Riva, A | 1 |
| Falvella, FS | 1 |
| Oreni, ML | 1 |
| Cattaneo, D | 1 |
| Cheli, S | 1 |
| Renisi, G | 1 |
| Di Cristo, V | 1 |
| Lupo, A | 1 |
| Clementi, E | 1 |
| Rusconi, S | 1 |
| Galli, M | 1 |
| Ridolfo, AL | 1 |
| Di Fusco, D | 1 |
| Erba, F | 1 |
| Mushiroda, T | 2 |
| Rufini, S | 1 |
| Buonomo, E | 1 |
| Giardina, E | 1 |
| Scarcella, P | 1 |
| Roca, B | 1 |
| Munderi, P | 1 |
| Snowden, WB | 1 |
| Walker, AS | 1 |
| Kityo, C | 1 |
| Mosteller, M | 1 |
| Kabuye, G | 1 |
| Thoofer, NK | 1 |
| Ssali, F | 1 |
| Gilks, CF | 1 |
| Hughes, AR | 1 |
| Chantarangsu, S | 1 |
| Mahasirimongkol, S | 1 |
| Kiertiburanakul, S | 1 |
| Sungkanuparph, S | 1 |
| Manosuthi, W | 1 |
| Tantisiriwat, W | 1 |
| Charoenyingwattana, A | 1 |
| Sura, T | 1 |
| Takahashi, A | 1 |
| Kubo, M | 1 |
| Kamatani, N | 1 |
| Chantratita, W | 1 |
| Nakamura, Y | 1 |
| Gao, S | 1 |
| Gui, XE | 1 |
| Liang, K | 1 |
| Liu, Z | 1 |
| Hu, J | 1 |
| Dong, B | 1 |
| Paximadis, M | 1 |
| Schramm, DB | 2 |
| Gray, GE | 2 |
| Sherman, G | 1 |
| Coovadia, A | 1 |
| Tiemessen, CT | 2 |
| Martin, AM | 1 |
| Nolan, D | 1 |
| James, I | 1 |
| Cameron, P | 1 |
| Keller, J | 1 |
| Moore, C | 1 |
| Phillips, E | 1 |
| Christiansen, FT | 1 |
| Mallal, S | 1 |
| Gatanaga, H | 1 |
| Yazaki, H | 1 |
| Tanuma, J | 1 |
| Honda, M | 1 |
| Genka, I | 1 |
| Teruya, K | 1 |
| Tachikawa, N | 1 |
| Kikuchi, Y | 1 |
| Oka, S | 1 |
| Donninger, S | 1 |
| Meddows-Taylor, S | 1 |
| Coovadia, AH | 1 |
| Sherman, GG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Short Duration Exclusive Breastfeeding With Abrupt Weaning to Reduce the Risk of Mother-to-Child HIV Transmission[NCT00310726] | 1,435 participants (Actual) | Interventional | 2001-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for nevirapine and Genetic Predisposition
| Article | Year |
|---|---|
[Future direction of pharmacogenomics: identification of genes associated with risk of adverse drug reactions using genome-wide association study].
Topics: Anticonvulsants; Carbamazepine; Dideoxynucleosides; Drug Eruptions; Genetic Predisposition to Diseas | 2014 |
Pharmacogenomics of antiretrovirals.
Topics: Alkynes; Anti-Retroviral Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Ce | 2008 |
1 trial available for nevirapine and Genetic Predisposition
| Article | Year |
|---|---|
Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Hypersensitivity; Gene Frequen | 2011 |
13 other studies available for nevirapine and Genetic Predisposition
| Article | Year |
|---|---|
Association of SNPs in HLA-C and ZNRD1 Genes With HIV-1 Mother-to-Child Transmission in Zambia Population.
Topics: Adult; Anti-HIV Agents; DNA-Binding Proteins; Female; Genetic Predisposition to Disease; Genotype; H | 2021 |
Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility.
Topics: Anti-HIV Agents; Case-Control Studies; Genetic Predisposition to Disease; Genotype; Glutathione Tran | 2017 |
A multivariate genetic analysis confirms rs5010528 in the human leucocyte antigen-C locus as a significant contributor to Stevens-Johnson syndrome/toxic epidermal necrolysis susceptibility in a Mozambique HIV population treated with nevirapine.
Topics: Adult; Alleles; Anti-HIV Agents; Case-Control Studies; Female; Gene Frequency; Genetic Predispositio | 2018 |
Polymorphisms in TH1-TH2 cytokine and receptor genes associated with risk of vertical HIV transmission, in Mumbai, India.
Topics: Anti-HIV Agents; Cohort Studies; Cytokines; Gene Frequency; Genetic Predisposition to Disease; Genot | 2018 |
Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2018 |
HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis susceptibility in a population from Mozambique.
Topics: Alleles; Anti-HIV Agents; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; | 2014 |
A pharmacogenetics study in Mozambican patients treated with nevirapine: full resequencing of TRAF3IP2 gene shows a novel association with SJS/TEN susceptibility.
Topics: Adaptor Proteins, Signal Transducing; Adult; Alleles; Anti-HIV Agents; Black People; Exons; Genetic | 2015 |
Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash.
Topics: Anti-HIV Agents; Chromosomes, Human, Pair 6; Drug Eruptions; Genetic Predisposition to Disease; Geno | 2011 |
HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alleles; Anti-HIV Agents; Asian People; CD4 Lymphocyte Co | 2012 |
Influence of intragenic CCL3 haplotypes and CCL3L copy number in HIV-1 infection in a sub-Saharan African population.
Topics: Africa South of the Sahara; Anti-HIV Agents; CD4 Antigens; Chemokine CCL3; Female; Gene Dosage; Gene | 2013 |
Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts.
Topics: Adult; Cohort Studies; Drug Hypersensitivity; Female; Genetic Predisposition to Disease; HLA Antigen | 2005 |
HLA-Cw8 primarily associated with hypersensitivity to nevirapine.
Topics: Adult; Anti-HIV Agents; Drug Hypersensitivity; Female; Genetic Predisposition to Disease; HIV Infect | 2007 |
African infants' CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Chemokine CCL3; Chemokine CCL4; Chemokine CCL5; Chemok | 2007 |